In a report released today, Hartaj Singh from Oppenheimer maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report). The company’s shares closed yesterday at $126.66.
According to TipRanks, Singh is a 5-star analyst with an average return of 9.2% and a 43.92% success rate. Singh covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Sarepta Therapeutics, and Biomea Fusion.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $169.47.
Based on Sarepta Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $396.78 million and a net profit of $45.66 million. In comparison, last year the company earned a revenue of $258.43 million and had a GAAP net loss of $109.24 million
Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Most recently, in March 2024, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 15,000.00 shares for a total of $1,848,795.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics (SRPT) Company Description:
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
